Kadderum

Eltrombopag, the active ingredient in Kadderum, is a thrombopoietin receptor agonist presented as an oral tablet for oral use. It is indicated for chronic immune thrombocytopenia, severe aplastic anemia, and hepatitis C‑associated thrombocytopenia in appropriate patients.

GNH USA supplies Kadderum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing reliable, quality‑assured medication across multiple therapeutic areas. The company adheres to stringent regulatory standards and offers comprehensive logistics support for global distribution.

Eltrombopag is used to treat disorders characterized by low platelet production.

- Chronic immune thrombocytopenia (ITP): Increases platelet counts to reduce bleeding risk. - Severe aplastic anemia: Stimulates platelet production as part of supportive therapy. - Hepatitis C‑associated thrombocytopenia: Improves platelet levels in patients with liver disease.

Eltrombopag may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Fatigue - Elevated liver enzymes

Serious or Rare Side Effects: - Hepatotoxicity - Thromboembolic events - Severe skin reactions such as Stevens‑Johnson syndrome

When prescribing Eltrombopag, clinicians should consider several precautionary measures to ensure patient safety.

- Baseline liver function: Assess hepatic enzymes before initiating therapy. - Monitor platelet counts: Adjust dose based on regular platelet monitoring. - Cardiovascular risk: Evaluate for history of thromboembolic disease. - Concomitant medications: Review for potential interactions affecting metabolism. - Pregnancy and lactation: Use only if potential benefit justifies potential risk; data limited. - Store at ambient temperature: Keep below 25 °C in original packaging, protect from moisture.

Eltrombopag can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): May markedly reduce drug exposure. - Antacids containing polyvalent cations (e.g., aluminum, magnesium): Can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): May increase plasma levels. - Warfarin: May enhance anticoagulant effect; monitor INR. - Live vaccines: Potentially reduced efficacy; assess risk/benefit.